Exscientia lands $26 mln Series B
UK-based Exscientia, an AI-driven drug discovery company, has secured $26 million in Series B financing. The investors were Celgene Corporation, GT Healthcare Capital Partners and Evotec AG.
7 January 2019•1 min read
